This trial is evaluating whether Dalbavancin will improve 13 primary outcomes in patients with Gram-Positive Bacterial Infections. Measurement will happen over the course of 4 weeks from the start of dalbavancin therapy.
This trial requires 60 total participants across 1 different treatment group
This trial involves a single treatment. Dalbavancin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"We can conclude that antibiotics can cure most cases of gram-positive bacterial bacterial infections. However, this cure is incomplete unless the disease has been treated for three weeks for gram-positive bacteria and for one week for gram-negative bacteria." - Anonymous Online Contributor
"More than 6% of Americans get a gram-positive bacterial infection a year, similar to national rates reported in the CDC reports. The percentage is increasing over time in children and younger adults." - Anonymous Online Contributor
"Gram-positive bacteria and their virulence factors are present in a wide range of different infections. A major role for a number of these is the ability to adhere to host tissue during infection, which facilitates host damage and disease. Infections that are not caused by gram-negative bacteria can be associated with gram-positive bacteria that adher to host proteins.\n" - Anonymous Online Contributor
"Treatment-based on a culture result (negative/positive) for gram-positive organisms is associated with lower rates of Gram-negative bacteremia and mortality than treatment based on culture results for all common pathogens. ClinicalTrials.gov: NCT00361678." - Anonymous Online Contributor
"Most children with bacterial infections are asymptomatic and have no clinically evident signs. Some signs can be identified on examinations and physical examinations. The presence of fever, enlarged chest and enlarged liver or spleen are indicative of bacterial pneumonia. Abdominal tenderness may indicate abscess or peritonitis. Hematologic abnormalities may suggest sepsis, and neurological defects may indicate meningitic infection in infants. Children with gastroenteritis may present with abdominal pain or vomiting. Fever, vomiting, and diarrhea may also be the presenting signs of gastroenteritis associated with bacterial infections." - Anonymous Online Contributor
"A common way of categorizing infectious agents in immunocompromised individuals is by their susceptibility to tetracycline, which can be used to characterize the organism in question. The present review focuses mostly on gram-positive bacterial infections. In this regard, the following organisms are all susceptible to tetracycline: Streptococcus pneumoniae, Neisseria meningitidis, Streptococcus pyogenes, and Haemophilus influenzae Type b." - Anonymous Online Contributor
"Antibiotics are a common treatment for most infections by gram-positive bacteria. In many situations, there is controversy whether to use antibiotics in certain groups of children. Clinical trials, however, are scarce and not often cited. Antibiotic resistance is increasing worldwide, so antibiotics will likely remain an important part of treatment for most infections caused by gram-positive bacteria. Clinical trials of antibiotics in children with certain types of infections are needed to help clarify who will benefit from treatment." - Anonymous Online Contributor
"The frequency and proportion of the treatment regimens are largely defined by the dalbavancin label-manufacturer's clinical experience in the management of the respective drug. These are discussed in detail, including possible interactions with concomitant agents and appropriate dosing, in the following sections. The dalbavancin label does not provide information on dosing in combination therapies." - Anonymous Online Contributor
"These include nausea and vomiting, headache, dizziness, and abnormal liver tests. When discontinuation of therapy is necessary, a delay of 7 days is recommended. People with a history of agranulocytosis should not restart dalbavancin and, moreover, should stop taking other oral antiphagocytic agents for 3 months before starting dalbavancin if they had had agranulocytosis." - Anonymous Online Contributor
"In a recent study, findings indicate that a single-center study in Taiwan provided reliable and reliable data which should contribute to the prevention of complications of this microbe. To obtain a clearer view of the problem, additional multi-center, multi-national research should continue." - Anonymous Online Contributor
"Only 12 of the 23 drugs studied were effective against gram-positive infections that were resistant to common antibiotics such as β-lactams and aminoglycosides. However, there were several effective compounds for the treatment of S. aureus bacteremia, including ceftriaxone, linezolid, and arbekacin. Most importantly, new antibiotics were effective against MDRSE and MMRSA, but more studies are needed to validate their efficacies." - Anonymous Online Contributor
"For those with a positive microbiological culture and without apparent risk factors, the mortality is very low (4.5% according to the NINDS criteria). In contrast, mortality is substantial among patients with a known or high risk for MRSA and/or Enterococcus spp. Infections with MRSA were associated with a high mortality irrespective of their etiology. Mortality remains very low for those with E coli or S pneumoniae bacteremia." - Anonymous Online Contributor